Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 1998

View Archived Issues

LeukoSite: year-end 1997 highlights

The effects of NPY antagonist BIBP-3226 on blood pressure and heart rate

Cypress Bioscience: Q4 and year-end 1997 highlights

Gilead: Q4 and year-end 1997 highlights

Genome Therapeutics and Schering-Plough expand antiinfectives alliance

Alliance formed for development of oral vaccines from plants

Lilly expands product options for Ligand

FDA advisory panel to review TMR using Heart Laser System

FDA Advisory Committee will meet to discuss Myotrophin

New potassium channel activators from American Home

Japanese academics collaborate in the study of oral platinum complex

SmithKline Beecham claims indolines for CNS disorders

Allergan develops retinoid-like compounds

Antimigraine agent for nasal or oral administration disclosed by Pierre Fabre

Inhibitors of cholesterol biosynthesis under study at Pfizer

New melanoma immunotherapy approaches show clinical potential

First launch for Synthelabo antihistamine

Patient enrollment complete for Gd-Tex phase II trial

FDA approves ocular antiinflammatory agent

Biomatrix and Novartis sign distribution agreement for Synvisc

Novel anti-HIV compound acts by inhibiting HIV-1 transcription

Taylor acquires anesthetic products from Janssen

Polydex receives continuing funding for contraceptive research

Inex finalizes acquisition of Lynx antisense assets

Detrusitol launched in U.K. and Germany

Antitumor TEPA analogue described by Lithuanian researchers

Bone Care International submits NDA for oral one-alpha D2

Crixivan gets traditional FDA approval

Diovan HCT approved in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...